{
    "clinical_study": {
        "@rank": "14985", 
        "acronym": "PROTEC", 
        "arm_group": {
            "arm_group_label": "DMF administered per the approved label", 
            "arm_group_type": "Experimental", 
            "description": "dimethyl fumarate (DMF) administered per the approved dosage in the country where DMF has received marketing authorization"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to estimate the annualized relapse rate (ARR) in\n      subjects with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl\n      fumarate (DMF) over a 12-month period.\n\n      The secondary objectives of this study in this population are to assess the impact of DMF\n      over a 12-month period on patient-reported health-related quality of life (HRQoL) outcomes,\n      additional clinical effectiveness outcomes, and health economics-related outcomes, and to\n      characterize patient-reported adherence to DMF."
        }, 
        "brief_title": "A Study Evaluating the Effectiveness of Tecfidera\u2122 (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsing-Remitting Multiple Sclerosis", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and satisfy the\n             approved therapeutic indication for DMF (per the local DMF product information).\n\n          -  Must be na\u00efve to DMF, Fumaderm\u00ae, and other compounded fumarates, and to MS therapies\n             that are primarily prescribed second-line (e.g., natalizumab, fingolimod) and to\n             alemtuzumab.\n\n          -  Have a recent complete blood count (CBC) that does not preclude the subject's\n             participation in the study, in the judgment of the Investigator.\n\n        Key Exclusion Criteria:\n\n          -  Are unwilling or unable to comply with study requirements, or are deemed unsuitable\n             for study participation as determined by the Investigator.\n\n          -  Have major comorbid conditions that preclude participation in the study, as\n             determined by the Investigator.\n\n          -  Are pregnant, unless DMF is clearly needed and the potential benefit of DMF to the\n             subjects justifies the potential risk to the fetus, in the judgment of the\n             Investigator (in all countries except Austria). In Austria, pregnant subjects are\n             excluded from participation in the study.\n\n          -  Are women of childbearing potential and are not using appropriate contraception (per\n             the local DMF product information) as determined by the Investigator.\n\n          -  Women who are breastfeeding may be excluded (per the local DMF product information)\n             at the discretion of the Investigator.\n\n          -  Have previously received or are receiving treatment with MS therapies primarily used\n             second-line (e.g., natalizumab, fingolimod) or alemtuzumab, or are currently\n             receiving and planning to continue on other disease-modifying therapies for RRMS.\n\n          -  Are hypersensitive to the active ingredient in the DMF drug product (i.e., DMF) or to\n             any of the excipients listed in the local DMF product information.\n\n          -  Current enrollment in any clinical trial except for the Biogen Idec DMF Pregnancy\n             Exposure Registry or other studies that, according to the study Medical Director, do\n             not conflict with this study (e.g., health economics studies or local registries).\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1080", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930708", 
            "org_study_id": "109MS408", 
            "secondary_id": "2013-001656-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "DMF administered per the approved label", 
                "description": "120 mg capsule oral twice daily (BID) during the first week of the treatment period", 
                "intervention_name": "dimethyl fumarate (DMF)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tecfidera", 
                    "DMF", 
                    "BG00012"
                ]
            }, 
            {
                "arm_group_label": "DMF administered per the approved label", 
                "description": "240 mg capsule oral twice daily (BID) for the remainder of the treatment period", 
                "intervention_name": "dimethyl fumarate (DMF)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tecfidera", 
                    "BG00012", 
                    "DMF"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dimethyl fumarate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "BG-12", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 2T9"
                    }, 
                    "name": "Multiple Sclerosis Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint John", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E2K 5S9"
                    }, 
                    "name": "Private Community Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera\u2122 (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "Spain: Spanish Agency of Medicines", 
                "Austria: Agency for Health and Food Safety", 
                "Czech Republic: State Institute for Drug Control", 
                "Slovakia: State Institute for Drug Control", 
                "Hungary: National Institute of Pharmacy", 
                "Canada: Health Canada", 
                "Portugal: National Authority of Medicines and Health Products, IP (INFARMED)", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Annualized Relapse Rate (ARR)", 
            "safety_issue": "No", 
            "time_frame": "12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930708"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Multiple Sclerosis Impact Scale (MSIS-29) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in Modified Fatigue Impact Scale-5 Item (MFIS-5) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in EQ-5D 5 level version (EQ-5D-5L) index", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in Patient-Reported Indices for Multiple Sclerosis-Activity Limitations (PRIMUS-Activity Limitations) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in Work Productivity and Activity Impairment-Multiple Sclerosis version (WPAI-MS) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from Baseline in Beck Depression Inventory-Fast Screen (BDI-Fast Screen) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Proportion of subjects with confirmed (24-week) Expanded Disability Status Scale (EDSS) progression", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Annualized Relapse Rate (ARR) at Baseline (i.e., over the 12 months prior to enrollment) and at Month 6", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 Months"
            }, 
            {
                "measure": "The proportion of subjects relapsed", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Number of subjects who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Proportion of subjects who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Proportion of subjects who report taking the prescribed DMF dose", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of subjects who report taking the prescribed DMF dose", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Reasons reported by subjects for not taking prescribed DMF dose", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Change from baseline in EQ Visual Analog Scale (EQVAS) score", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}